Call for Abstract
Scientific Program
3rd International Conference on Alzheimer’s Disease & Dementia, will be organized around the theme “Diagnosis Approaches of Dementia and Alzheimers Disease”
Dementia 2015 is comprised of 10 tracks and 10 sessions designed to offer comprehensive sessions that address current issues in Dementia 2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Biomarkers
- Track 1-2Novel approaches in biomarkers
- Track 1-3Living with Alzheimers disease
- Track 1-4Patients psychological changes
- Track 1-5Neuropathology
- Track 1-6Neuropsychology
- Track 1-7Early detection possibilities
- Track 1-8Different diagnosis procedures
- Track 1-9New methods in diagnosis
- Track 1-10Normal brain aging
- Track 2-1Amyloid and Tau imaging
- Track 2-2Imaging animal models
- Track 2-3Imaging and genetics
- Track 2-4New methodsin imaging
- Track 2-5Structural and functional MRI
- Track 2-6Positron emission tomography
- Track 2-7MR spectroscopy
- Track 2-8EEG and brain mapping
- Track 2-9SPECT imaging
- Track 2-10Imaging correlates of clinical, cognitive, and biomarker variables
- Track 3-1Aging
- Track 3-2Prions and Alzheimers disease
- Track 3-3Cellular signalling and cell to cell transmission?
- Track 3-4Oxidative damage
- Track 3-5Mitochondrial dysfunction
- Track 3-6Autoimmunity in Alzheimers
- Track 3-7Blood-brain barrier and transport
- Track 3-8Neurogenesis and stem cells
- Track 3-9Cell death
- Track 4-1Amyloid Protein and Alzheimers Disease
- Track 4-2Amyloid beta metabolism in Alzheimers
- Track 4-3Brain accumulation of toxic amyloid beta
- Track 4-4Amyloid Plaques and Neurofibrillary Tangles
- Track 4-5Amyloid neuroimaging and biomarkers
- Track 4-6Amyloidosis and Neurodegeneration
- Track 4-7The amyloid hypothesis and potential treatments
- Track 4-8Amyloid beta deposition, cognition and brain volume
- Track 5-1Transgenic models
- Track 5-2Pharmacological and lesion models
- Track 5-3Natural and seminatural models
- Track 5-4Primate models
- Track 5-5Zebra fish models
- Track 5-6Animal models of human cognitive aging
- Track 5-7Development of new animal models
- Track 5-8Genetics of translational models
- Track 5-9Protein-protein interactions
- Track 5-10Ethical issues with animal models
- Track 6-1Education and training of medical professionals
- Track 6-2Care and quality of life
- Track 6-3Caregiver support
- Track 6-4Person centered care
- Track 6-5Cognitive training
- Track 6-6Support and training for informal and professional carers
- Track 6-7Putting scientific knowledge into practice
- Track 6-8Non-pharmacological Interventions
- Track 6-9Functional foods
- Track 6-10Art, music and life style
- Track 7-1Neurological changes in brain
- Track 7-2Genetic associations and susceptibility genes
- Track 7-3Epidemiology and prevalence
- Track 7-4Amyloid protein: A protein of great concern
- Track 7-5Can Alzheimers disease be prevented or treated?
- Track 7-6Role of apolipoprotein E
- Track 7-7Age an important factor for Alzheimers disease?
- Track 7-8Brain trauma
- Track 7-9Metabolic syndrome and Alzheimers disease
- Track 7-10Protein misfolding, aggregation and toxicity
- Track 7-11Disease-causing mutations
- Track 7-12Histone modification, DNA methylation
- Track 8-1Neurodegenerative diseases
- Track 8-2Geriatric emergency medicine
- Track 8-3Geriatric diagnostics
- Track 8-4Geriatric neurology
- Track 8-5Geriatric oncology
- Track 8-6Geriatric psychiatry or psychogeriatrics
- Track 8-7Geriatric pharmacotherapy
- Track 8-8Alcohol addiction and mental health
- Track 8-9Nutritional deficiency
- Track 8-10Preventions: Mental activity and healthy lifestyle
- Track 9-1Vascular dementia
- Track 9-2Dementia with lewy bodies
- Track 9-3Fronto-temporal dementia
- Track 9-4Rarer causes of dementia
- Track 9-5Creutzfeldt-Jakob disease
- Track 9-6HIV-related cognitive impairment
- Track 9-7Mild cognitive impairment
- Track 9-8Korsakoffs syndrome
- Track 10-1Abeta, truncated and pGlu-Abeta
- Track 10-2Immunotherapy
- Track 10-3Neurotransmitter-based targets
- Track 10-4Anti-inflammatory targets
- Track 10-5Anti-oxidants
- Track 10-6Neurotrophic factors
- Track 10-7Protein aggregation
- Track 10-8Deep brain stimulation
- Track 10-9Misfolding and chaperones
- Track 10-10Gene therapy
- Track 10-11Nanotechnology
- Track 10-12Drug-delivery systems